These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 23283612)

  • 1. Gingival pain: an unusual side effect of ziprasidone.
    Raghunath A
    BMJ Case Rep; 2013 Jan; 2013():. PubMed ID: 23283612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute dystonia after initial doses of ziprasidone: a case report.
    Yumru M; Savas HA; Selek S; Savas E
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jun; 30(4):745-7. PubMed ID: 16580766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary hesitancy and retention caused by ziprasidone.
    Xomalis D; Bozikas VP; Garyfallos G; Nikolaidis N; Giouzepas J; Fokas K
    Int Clin Psychopharmacol; 2006 Jan; 21(1):71-2. PubMed ID: 16317320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ziprasidone-associated pedal edema in the treatment of schizophrenia.
    Ku HL; Su TP; Chou YH
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jul; 30(5):963-4. PubMed ID: 16624468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-dose ziprasidone associated with QT interval prolongation.
    Witsil JC; Zell-Kanter M; Mycyk MB
    Am J Emerg Med; 2012 Jun; 30(5):837.e1-2. PubMed ID: 21641143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transient agranulocytosis associated with ziprasidone in a 45-year-old man on hemodialysis.
    Iskandar JW; Vance JE; Kablinger A; Kavuru B
    J Clin Psychopharmacol; 2015 Jun; 35(3):347-8. PubMed ID: 25874914
    [No Abstract]   [Full Text] [Related]  

  • 7. High-dose ziprasidone-induced acute dystonia.
    Rosenfield PJ; Girgis RR; Gil R
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):546-7. PubMed ID: 17123682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder.
    Miceli JJ; Tensfeldt TG; Shiovitz T; Anziano RJ; O'Gorman C; Harrigan RH
    Clin Ther; 2010 Mar; 32(3):472-91. PubMed ID: 20399985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ziprasidone-associated mania: a review and report of 2 additional cases.
    Keating AM; Aoun SL; Dean CE
    Clin Neuropharmacol; 2005; 28(2):83-6. PubMed ID: 15795551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching among antipsychotics in everyday clinical practice: focus on ziprasidone.
    Rossi A; Cañas F; Fagiolini A; Larmo I; Levy P; Montes JM; Papageorgiou G; Sturlason R; Zink M; Correll CU
    Postgrad Med; 2011 Jan; 123(1):135-59. PubMed ID: 21293094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroleptic malignant syndrome induced by ziprasidone on the second day of treatment.
    Ozen ME; Yumru M; Savas HA; Cansel N; Herken H
    World J Biol Psychiatry; 2007; 8(1):42-4. PubMed ID: 17366349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The potential relationship between QTc interval prolongation and ziprasidone treatment: three cases.
    Eker SS; Sarandol A; Akkaya C; Sivrioglu EY; Kirli S
    J Psychopharmacol; 2009 Nov; 23(8):993-6. PubMed ID: 18635710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ziprasidone-induced hypersensitivity syndrome in an aged schizophrenia patient.
    Tsai CF; Tsai SJ; Hwang JP
    Int J Geriatr Psychiatry; 2005 Aug; 20(8):797-9. PubMed ID: 16035110
    [No Abstract]   [Full Text] [Related]  

  • 14. A patient using ziprasidone with polydipsia, seizure, hyponatremia and rhabdomyolysis.
    Akkaya C; Sarandol A; Sivrioglu EY; Kotan Z; Kirli S
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Dec; 30(8):1535-8. PubMed ID: 16820256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Oral Ziprasidone and Oral Haloperidol on QTc interval in patients with Schizophrenia or Schizoaffective disorder.
    Miceli JJ; Tensfeldt TG; Shiovitz T; Anziano R; O'Gorman C; Harrigan RH
    Pharmacotherapy; 2010 Feb; 30(2):127-35. PubMed ID: 20099987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Probable association between ziprasidone and worsening hypertension.
    Villanueva N; Markham-Abedi C; McNeely C; Diaz FJ; de Leon J
    Pharmacotherapy; 2006 Sep; 26(9):1352-7. PubMed ID: 16945059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute dystonia, akathisia, and parkinsonism induced by ziprasidone.
    Praharaj SK; Jana AK; Sarkhel S; Sinha VK
    Am J Ther; 2014; 21(2):e38-40. PubMed ID: 23698184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of switching to ziprasidone in italian patients with acute exacerbation of schizophrenia: an open-label trial.
    Mencacci C;
    Pharmacopsychiatry; 2012 Sep; 45(6):236-40. PubMed ID: 22592506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urticaria and angio-oedema due to ziprasidone.
    Akkaya C; Sarandol A; Aydogan K; Kirli S
    J Psychopharmacol; 2007 Jul; 21(5):550-2. PubMed ID: 17446198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ziprasidone and weight gain.
    Jaworowski S; Hauser S; Mergui J; Hirsch H
    Clin Neuropharmacol; 2004; 27(2):99-100. PubMed ID: 15252274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.